Meningococcal B Vaccine Efficacy in Children at High Risk for Meningococcal Disease

Meningococcal B vaccine was immunogenic in children with splenic dysfunction and to a lesser degree in those with complement deficiency.

A quadrivalent conjugate meningococcal vaccine that covers serotypes A, C, W, and Y is recommended for children with high-risk conditions such as splenic dysfunction and complement deficiency starting at age 2 years. However, a newer vaccine for meningococcal B disease is not currently recommended in these children.

In an open-label study, researchers tested the efficacy of the meningococcal B vaccine (Bexsero) given in two doses two months apart to children aged 2 to 17 years (112 with splenic dysfunction or asplenia, 40 with terminal complement deficiency, and 87 healthy controls). Immunogenicity was measured by serum bactericidal activity (SBA) using exogenous and endogenous complement. Results were as follows:

Postimmunization SBA titers …

Reviewing Author

Deborah Lehman, MD

Disclosures

Nothing to disclose

Deborah Lehman, MD

Disclosures

Nothing to disclose

Meningococcal B Vaccine Efficacy in Children at High Risk for Meningococcal Disease

Topics

Reviewing Author